Mithra 30-day cash runway
Mithra's cash levels have continued to dwindle in recent months, and the company now indicates runway until early March. While no major deal announcements (e.g., US Donesta licensing, sale of CDMO and therapeutics businesses) have come through so far and with few short-term financing options available, combined with its pledged asset risk, we take precautionary measures. We adjust our TP from € 1.70 to € 1.00 and move from a Hold to a Reduce rating.Mithra Pharmaceuticals SA is a Belgium-based company active in the pharmaceutical industry. The Company is dedicated to provide products and services for the fertility, contraception and menopause of women. It has a number of patent families regarding Estetrol (E4), a natural estrogen produced by the human foetus, which enables the investigation of fertility and contraception products. Mithra is focused on the development of two late-stage E4-based products: Estelle, a 5th generation oral contraceptive, and Donesta, a hormone therapy for Vasomotor Symptoms in menopause. Mithra develops a contraceptive vaginal ring called Myring and Zoreline, a biodegradable subcutaneous implant for hormone dependant cancer.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.